Ferry Ferdiansyah Sofian

Dr. Ferry Ferdiansyah Sofian

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in Heliyon
Verified
Journal Article
Open access
YHYedi Herdiana
Yedi Herdiana
FSFerry Ferdiansyah Sofian
Ferry Ferdiansyah Sofian
SSSHAHARUM SHAMSUDDIN
SHAHARUM SHAMSUDDIN
TRTaofik Rusdiana
Taofik Rusdiana
Halal is a crucial concept for Muslim consumers regarding consumed products, including pharmaceutical ingredients, which are essential in modern medicine. To address the issue of using porcine-sourced ingredients in pharmaceuticals, it is essential to search for halal alternatives derived from poultry, animal by-products from meat processing, marine sources, and plants. However, the complexity of this problem is further compounded by the rapid advances in innovation and technology, which can lead to adulteration of ingredients derived from pigs. Other challenges include the sustainability of alternative materials, management of waste or by-products practice, halal awareness, certification, government policies, religious adherence of consumers, food suppliers, marketers, and purchasing of products. The importance of halal and non-halal problems, specifically in the context of pharmaceutical materials, is still rarely discussed, including alternatives derived from poultry, animal by-products, marine sources, and plants. Due to the increasing global population, there is a growing need to increase awareness and concern among Muslim consumers for halal products, including pharmaceuticals. Therefore, this research aimed to investigate the importance of halal and non-halal issues in pharmaceutical ingredients, the potential impact on the Muslim community, as well as opportunities and challenges in the search for alternative ingredients.

10 July 2023 in Molecules
Verified
Journal Article
Open access
PDF file
YHYedi Herdiana
Yedi Herdiana
SSSriwidodo Sriwidodo
Sriwidodo Sriwidodo
FSFerry Ferdiansyah Sofian
Ferry Ferdiansyah Sofian
GWGofarana Wilar
Gofarana Wilar
ADAjeng Diantini
Ajeng Diantini
Breast cancer (BC) is a complex and heterogeneous disease, and oxidative stress is a hallmark of BC. Oxidative stress is characterized by an imbalance between the production of reactive oxygen species (ROS) and antioxidant defense mechanisms. ROS has been implicated in BC development and progression by inducing DNA damage, inflammation, and angiogenesis. Antioxidants have been shown to scavenge ROS and protect cells from oxidative damage, thereby regulating signaling pathways involved in cell growth, survival, and death. Plants contain antioxidants like ascorbic acid, tocopherols, carotenoids, and flavonoids, which have been found to regulate stress signaling and PCD in BC. Combining different antioxidants has shown promise in enhancing the effectiveness of BC treatment. Antioxidant nanoparticles, when loaded with antioxidants, can effectively target breast cancer cells and enhance their cellular uptake. Notably, these nanoparticles have shown promising results in inducing PCD and sensitizing breast cancer cells to chemotherapy, even in cases where resistance is observed. This review aims to explore how nanotechnology can modulate stress signaling and PCD in breast cancer. By summarizing current research, it underscores the potential of nanotechnology in enhancing antioxidant properties for the treatment of breast cancer.

14 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YHYedi Herdiana
Yedi Herdiana
Yoga Windhu WardhanaYoga Windhu Wardhana
Yoga Windhu Wardhana
IKInsan Sunan Kurniawansyah
Insan Sunan Kurniawansyah
DGDolih Gozali
Dolih Gozali
Nasrul WathoniNasrul Wathoni
Nasrul Wathoni
FSFerry Ferdiansyah Sofian
Ferry Ferdiansyah Sofian
The deposition of monosodium urate (MSU) crystals within joint spaces produces a painful inflammatory condition known as gout, a specific form of arthritis. The condition calls for a combined curative and preventive management model. A new development in the approach to gout is that of NLRP3-targeted biologic agents, such as monoclonal therapies, to provide more accurate treatment by blocking specific pro-inflammatory cytokines. Nanoparticle drug delivery enhances biological availability and delivery to targets, which may increase therapeutic efficacy and decrease general toxicity. The preventive approach again cannot be ignored, mainly keeping up certain modifications in diet and weight, along with pharmacological therapies to reduce uric acid (UA) levels and to decrease the frequency of acute attacks. The advancement of genetic profiling of patients and biomarker discoveries drives the trend towards building individualized medicine and care, quickly gaining ground as the most effective method of delivering treatments to individual patients, moving away from one-size-fits-all treatments. The following paper aims to provide an updated account of the management of gout with a focus on recent developments, in order to enhance these approaches, the quality of life for patients with gout, and the standard of gout treatment.

14 February 2022 in Fitoterapia
Verified
Journal Article
Closed access
FSFerry Ferdiansyah Sofian
Ferry Ferdiansyah Sofian
ASAnas Subarnas
Anas Subarnas
MHMayuka Hakozaki
Mayuka Hakozaki
SUShota Uesugi
Shota Uesugi
TKTakuya Koseki
Takuya Koseki
YSYoshihito Shiono
Yoshihito Shiono

30 April 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
FSFerry Ferdiansyah Sofian
Ferry Ferdiansyah Sofian
TATakako Aboshi
Takako Aboshi
HKHadi kuncoro
Hadi kuncoro
DDDeden Indra Dinata
Deden Indra Dinata
YNYoshifumi Nishikawa
Yoshifumi Nishikawa

26 March 2022 in Magnetic Resonance in Chemistry
Verified
Journal Article
Closed access
FSFerry Ferdiansyah Sofian
Ferry Ferdiansyah Sofian
ASAnas Subarnas
Anas Subarnas
TKTakuya Koseki
Takuya Koseki
YSYoshihito Shiono
Yoshihito Shiono